Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

Vaccine

Volumn 27, Issue SUPPL. 2, 2009, Pages

  Holst, Johan ^a   Martin, Diana ^b   Arnold, Richard ^c   Huergo, Concepcion Campa ^d   Oster, Philipp ^e   O'Hallahan, Jane ^f   Rosenqvist, Einar ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^d FINLAY INSTITUTE   (Cuba)

^e NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^f MINISTRY OF HEALTH   (New Zealand)

Author keywords

Meningococcal disease; Neisseria meningitidis; Outer membrane vesicles; Vaccines for epidemic control

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PORIN A;

ANAPHYLACTOID PURPURA; ARTICLE; BRONCHIOLITIS; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CUBA; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; FEBRILE CONVULSION; FEVER; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEW ZEALAND; NORWAY; PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION; WILD TYPE;

BACTERIAL OUTER MEMBRANE PROTEINS; CUBA; DRUG STABILITY; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP B; NEW ZEALAND; NORWAY; SECRETORY VESICLES;

EID: 67349114815     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.071     Document Type: Article

References (85)

1. Trotter C.L., Gay N.J., and Edmunds W.J. The natural history of meningococcal carriage and disease. Epidemiol Infect 134 3 (2006) 556-566
2. Caugant D.A., Høiby E.A., Magnus P., Scheel O., Hoel T., Bjune G., et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 32 2 (1994) 323-330
3. Granoff D.M., Harrison L.H., and Borrow R. Meningococcal vaccines. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines. fifth edition (2008), WB Saunders, Philadelphia 399-434 [chapter 19]
4. Anonymous. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition (1998), World Health Organization
5. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.-M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299 2 (2008) 173-184
6. Finne J., Leinonen M., and Mäkela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2 8346 (1983) 355-357
7. Miller E., Salisbury D., and Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl 1 (2001) S58-67
8. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hughes J.M. Meningococcal disease. N Engl J Med 344 18 (2001) 1378-1388
9. Sharip A., Sorvillo F., Redelings M.D., Masola L., Wise M., and Nguyen D.M. Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatr Infect Dis J 25 3 (2006) 191-194
10. Trotter C.L., Chandra M., Cano R., Larrauri A., Ramsay M.E., Brehony C., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 31 1 (2007) 27-36
11. Sierra G.V.G., Campa H.C., Varacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14 2 (1991) 195-207 Discussion 208-10
12. Bjune G., Høiby E.A., Grønnesby J.K., Arnesen Ø., Holst Fredriksen J., Halstensen A., et al. Effect of outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway. Lancet 338 8775 (1991) 1093-1096
13. Martin D.R., Walker S.J., Baker M.G., and Lennon D.R. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 177 2 (1998) 497-500
14. Holst J, Aaberge IS, Oster P, Lennon D, Martin D, O'Hallahan J, et al. A 'tailor made' vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Euro Surveill 2003; 7(30), http://www.eurosurveillance.org/ViewArticle.aspx?.
15. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA 281 16 (1999) 1520-1527
16. Holst J., Feiring B., Næss L.M., Nordheim G., Kristiansen P., Høiby E.A., et al. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23 17-18 (2005) 2202-2205
17. Martin D.R., Riijne N., McCallum L., O'Hallahan J., and Oster P. The VR2 epitope on the PorA P1.7-2 4 protein is the major target for the immune response elicited by the strain-specific Group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 13 4 (2006) 486-491
18. Helting T.B., Guthorlein G., Blackkolb F., and Ronneberger H. Serotype determinant protein of Neisseria meningitides. Large scale preparation by direct detergent treatment of the bacterial cells. Acta Pathol Microbiol Scand [C] 89 2 (1981) 69-78
19. Poolman J.T. Polysaccharides and membrane vaccines. In: Mizrahi A. (Ed). Bacterial vaccines (1990), Wiley-Liss, New York 58-86
20. Frasch C.E., van Alphen L., Holst J., Poolman J., and Rosenqvist E. Preparation of outer membrane protein vaccines against meningococcal disease. In: Pollard A.J., and Maiden M.C.J. (Eds). Methods in molecular medicine, vol. 66. Meningococcal disease protocols (2001), Humana Press Inc., Totowa, NJ 81-107 [chapter 55]
21. Holst Fredriksen J., Rosenqvist E., Wedege E., Bryn K., Bjune G., Frøholm L.O., et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 14 2 (1991) 67-79 Discussion 79-80
22. Høiby E.A., Rosenqvist E., Frøholm L.O., Feiring B., Nøkleby H., and Rønnild E. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann 14 2 (1991) 147-155 Discussion 155-6
23. Rosenqvist E., Høiby E.A., Bjune G., Aase A., Halstensen A., Lehmann A.K., et al. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidids outer membrane vesicle vaccine. In: Brown F., and Haaheim L.R. (Eds). Modulation of the immune response to vaccine antigens, vol. 92 (1998), Develop Biol Stand, Karger, Basel 323-333
24. Tsai C., Frasch C.E., Rivera E., and Hochstein H.D. Measurement of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. J Biol Stand 17 3 (1989) 249-258
25. Wheeler J.X., Vipond C., and Feavers I. Exploring the proteome of meningococcal outer membrane vesicle vaccines. Proteomics Clin Appl 1 9 (2007) 1198-1210
26. Ferrari G., Garaguso I., Adu-Bobie J., Doro F., Tadder A.R., Biolchi A., et al. Outer membrane vesicles from group B Neisseria meningitidis Δgna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 6 6 (2006) 1856-1866
27. Uli L., Castellanos-Serra L., Betancourt L., Dominguez F., Barbera R., Sotolongo F., et al. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B Neisseria meningitidis: analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 6 11 (2006) 3389-3399
28. Vipond C., Suker J., Jones C., Tang C., Feavers I.M., and Wheeler J.X. Proteomic analysis of meningococcal outer membrane vesicle vaccine prepared from group B strain NZ98/254. Proteomics 6 11 (2006) 3400-3413
29. van der Ley P., and Poolman J.T. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun 60 8 (1992) 3156-3161
30. van den Dobbelsteen G.P., van Dijken H.H., Pillai S., and van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 25 13 (2007) 2491-2496
31. Claassen I., Meylis J., van der Ley P., Peeters C., Brons H., Robert J., et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14 10 (1996) 1001-1008
32. Cartwright K., Morris R., Rumke H., Fox A., Borrow R., Begg N., et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17 20-21 (1999) 2612-2619
33. Liu M.A., Friedman A., Oliff A.I., Tai J., Martinez D., Deck R.R., et al. A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes. Proc Natl Acad Sci USA 89 10 (1992) 4633-4637
34. Ulmer J.B., Burke C.J., Shi C., Friedman A., Donnelly J.J., and Liu M.A. Pore formation and mitogenicity in blood cells by the class 2 protein of Neisseria meningitidis. J Biol Chem 267 27 (1992) 19266-19271
35. Granoff D.M., Anderson E.L., Osterholm M.T., Holmes S.J., McHugh J.E., Belshe R.B., et al. Differences in the immunogenicity of three Haemophilus influenza type b conjugate vaccines in infants. J Pediatr 121 2 (1992) 187-194
36. Einhorn M.S., Weinberg G.A., Anderson E.I., Granoff P.D., and Granoff D.M. Immunogenicity in infants of Haemophilus influenza type b polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet 328 8502 (1986) 299-302
37. Anonymus. Liquid PedvaxHIB. Product description. Merck & Co., Inc., West Point, PA, January 2001.
38. Latz E., Franko J., Golenbock D.T., and Schreiber J.R. Haemophilus influenza type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol 172 4 (2004) 2431-2438
39. Koeberling O., Welsch J.A., and Granoff D.M. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine 25 10 (2007) 1912-1920
40. Koeberling O., Seubert A.K., and Granoff D.M. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with over-expressed fHbp and genetically-attenuated endotoxin. J Infect Dis 198 2 (2008) 262-270
41. Zollinger W.D., Donets M., Brandt B.L., Ionin B., Moran E.E., Schmeil D., et al. Multivalent group B meningococcal vaccine based on native outer membrane vesicles (NOMV) has potential for providing safe, broadly protective immunity. In: van Alphen L., van den Dobbelsteen G., and van der Ley P. (Eds). Abstract volume to the 16th international pathogenic Neisseria conference. Rotterdam 7-12 September (2008) 51 [oral presentation O35]
42. Keiser P.B., Moran E.E., Schmeil D.H., Pinto V.B., Coster T.S., Gibbs B.T., et al. A phase 1 study of the safety and immunogenicity of an intramuscular group B meningococcal NOMV vaccine made from an lpxL2 and synX deleted strain. In: van Alphen L., van den Dobbelsteen G., and van der Ley P. (Eds). Abstract volume to the 16th international pathogenic Neisseria conference. Rotterdam 7-12 September (2008) 273 [poster presentation P215]
43. Dalseg R., Wedege E., Haugen I.L., Holst J., and Haneberg B. Group B meningococcal OMV vaccine as a mucosal immunogen. Clin Immunol Immunopathol 76 1 (1995) S93
44. Haneberg B., Dalseg R., Wedege E., Høiby E.A., Haugen I.L., Oftung F., et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 66 4 (1998) 1334-1341
45. Haneberg B., and Holst J. Can nonliving nasal vaccines be made to work?. Expert Rev Vaccines 1 2 (2002) 227-232
46. Katial R.K., Brandt B.L., Moran E.E., Marks S., Agnello V., and Zollinger W.D. Immunogenicity and safety testing of a group B Intranasal meningococcal native outer membrane vesicle vaccine. Infect Immun 70 2 (2002) 702-707
47. Matsunami T., and Kolmer J.A. The relation of the meningococcal activity of the blood to resistance to virulent meningococci. J Immunol 3 3 (1918) 201-212
48. Heist G.D., Solis-Choen S., and Solis-Choen M. A study of the virulence of meningococci for man and of human susceptibility to meningococci infection. J Immunol 7 1 (1922) 1-33
49. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus I. The role of humoral antibodies. J Exp Med 129 6 (1969) 1307-1326
50. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13 9 (1995) 821-829
51. de Moraes J.C., Perkins B.A., Camargo M.C.C., Hidalgo N.T.R., Barbosa H.A., Sacchi C.T., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340 8827 (1992) 1074-1078
52. Holst J., Feiring B., Fuglesang J.E., Høiby E.A., Nøkleby H., Aaberge I.S., et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21 7-8 (2003) 734-737
53. O'Hallahan J., Lennon D., Oster P., Reid S., Mulholland K., and Martin D. From secondary prevention to primary prevention - a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 23 17-18 (2005) 2205-2209
54. Rosenqvist E., Bjaering Hansen N., Høiby E.A., Caugant D.A., Holst J., Namork E., et al. Development and evaluation of experimental meningococcal B: 4: P1.(7),4 outer membrane vesicle vaccine and evaluation in a mouse model. In: Nassif X., Quintin-Millet M.-J., and Taha M.-K. (Eds). Abstract volume to the 11th international pathogenic Neisseria conference. Nice 7-12 October (1998) 169
55. Thornton V., Lennon D., Rasanathan K., O'Hallahan J., Oster P., Stewart J., et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 24 9 (2006) 1395-1400
56. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., and Martin D. MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23 17-18 (2005) 2191-2196
57. Kelly C., Arnold R., Galloway Y., and O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 166 7 (2007) 817-823
58. Galloway Y., Stehr-Green P., McNicholas A., and O'Hallahan J. Use of an observational study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 38 2 (2009) 413-418
59. Oster P., O'Hallahan J., Aaberge I., Timan S., Ypma E., and Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 25 16 (2007) 3075-3079
60. Rosenqvist E., Høiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63 12 (1995) 4642-4652
61. Wenger J.D. Serogroup B meningococcal disease. New outbreaks, new strategies [editorial]. JAMA 281 16 (1999) 1541-1543
62. van der Voort E.R., van der Ley P., van der Biezen J., George S., Tunnela O., van Dijken H., et al. Specificity of human bactericidal antibodies against PorA P1.7 16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 64 7 (1996) 2745-2751
63. Tondella M.L., Popovic T., Rosenstein N.E., Lake D.B., Carlone G.M., Mayer L.W., et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The active bacterial core surveillance team. J Clin Microbiol 38 9 (2000) 3323-3328
64. Feiring B., Fuglesang J., Oster P., Naess L.M., Helland O.S., Tilman S., et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 13 7 (2006) 790-796
65. Sotolongo Padron F., Huergo C.C., Gil V.C., Diaz E.M.F., Valdespino I.E.C., and Gotera N.G. Cuban meningococcal BC vaccine: experience and contributions from 20 years of application. MEDICC Rev 9 1 (2007) 16-22. http://www.medicc.org/mediccreview/articles/mr_61.pdf
66. Martin D, Lopez L. The epidemiology of meningococcal disease in New Zealand in 2007. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research Ltd.; 2008. Available at http://www.moh.govt.nz/moh.nsf/pagesmh/8204/$File/meningo-annual-report-2007.pdf.
67. Martin D.R., and Lopez L. Has MeNZB™ controlled New Zealand's epidemic?. In: van Alphen L., van den Dobbelsteen G., and van der Ley P. (Eds). Abstract volume to the 16th international pathogenic Neisseria conference. Rotterdam 7-12 September (2008) 79-80 [oral presentation O63]
68. Loring B.J., Turner N., and Petousis-Harris H. MeNZB™ vaccine and epidemic control: when do you stop vaccinating?. Vaccine 26 47 (2008) 5899-5904
69. Lennon D. The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemic. N Z Med J 121 1270 (2008) 110-112. http://www.nzma.org.nz/journal/121-1270/2965/
70. Lennon D.R., Jackson C., and Thornley C. Why stop MeNZB vaccination? Supporting evidence for withdrawal of epidemic strain outer membrane vesicle (OMV) vaccine in New Zealand. In: van Alphen L., van den Dobbelsteen G., and van der Ley P. (Eds). Abstract volume to the 16th international pathogenic Neisseria conference. Rotterdam 7-12 September (2008) 65-66 [oral presentation O49]
71. O'Hallahan J., McNicholas A., Galloway Y., O'Leary E., and Roseveare C. Delivering a safe and effective strain specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 122 1291 (2009) 48-59. http://www.nzma.org.nz/journal/abstract.php?id=3504
72. Nøkleby H., Aavitsland P., O'Hallahan J., Feiring B., Tilman S., and Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25 16 (2007) 3080-3084
73. Taha M.-K., Zarantonelli M.L., Alonso J.-M., Næss L.M., Holst J., Feiring B., et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 25 14 (2007) 2537-2538
74. McNicholas A., Galloway Y., Stehr-Green P., Stewart R., Radke S., Sexton K., et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand 2004-2006. Hum Vaccines 3 5 (2007) 196-204
75. Tatley M.V., Kunac D.L., McNicholas A., Zhou L., Ballantyne S., Ashton J., et al. The intensive vaccines monitoring programme (IVMP): an electronic system to monitor vaccine safety in New Zealand. Vaccine 26 22 (2008) 2746-2752
76. Stehr-Green P., Galloway Y., Kieft C., and McNicholas A. The risk of bronchiolitis hospitalization following administration of a group B meningococcal vaccine in New Zealand. N Z Med J 120 1263 (2007) 1-4. http://www.nzma.org.nz/journal/120-1263/2746/content.pdf
77. Stehr-Green P., Radke S., Kieft C., Galloway Y., McNicholas A., and Reid S. The risk of simple febrile seizures after immunization with a new group B meningococcal vaccine, New Zealand. Vaccine 26 6 (2008) 739-742
78. Sexton K., McNicholas A., Galloway Y., Radke S., Kieft C., Stehr-Green P., et al. Henoch-Schönlein purpura and meningococcal B vaccination. Arch Dis Child 94 3 (2009) 224-226
79. Nøkleby H. Neurological adverse events of immunization: experience with an aluminium adjuvanted meningococcal B outer membrane vesicle vaccine. Expert Rev Vaccines 6 5 (2007) 863-869
80. Magnus P., Brubakk O., Nyland H., Wold B.H., Gjessing H.K., Brandt I., et al. Vaccination as teenagers against meningococcal disease and risk of chronic fatigue syndrome. Vaccine 27 1 (2009) 23-27
81. Holst J. Strategies for developing universal vaccines against serogroup B meningococcal disease. Human Vaccines 3 6 (2007) 290-294
82. Norheim G., Aase A., Caugant D.A., Høiby E.A., Fritzønn E., Tangen T., et al. Development and characterization of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 23 29 (2005) 3762-3774
83. Norheim G., Fritzønn E., Kristiansen P., Tangen T., Caugant D.A., Høiby E.A., et al. Prevention of serogroup A, C and W135 meningococcal disease in Africa with outer membrane vesicle vaccines. In: Apicella M.A., and Seifert H. (Eds). Fourteenth international pathogenic Neisseria conference. Milwaukee, Wisconsin, USA (2004) 181
84. Miller E, Pollard AJ, Borrow R, Findlow J, Dawson T, Morant A, et al. Safety and immunogenicity of Novartis meningococcal serogroup B vaccine (MenB vaccine) after three doses administered in infancy. Abstract to ESPID, Graz, Austria; 2008.
85. Feavers I.M., and Pizza M. Meningococcal protein antigens and vaccines. Vaccine 27 S2 (2009) B41-B49